

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

NCT03993262

Status	RECRUITING
Phase	Phase 2
Sponsor	Jena University Hospital
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (5)

- Clinically diagnosed severe autoimmune encephalitis (defined as mRS e 3) with autoantibodies to neuronal surface proteins in cerebrospinal fluid and / or serum
- Pretreatment with rituximab
- Age e18 years
- signed informed consent
- Women of childbearing potential (up to 2 years after menopause): negative pregnancy test

Exclusion (7)

- pregnancy/breast-feeding
- acute infiltrative pulmonary and pericardial disease
- malignant tumor under current chemotherapy
- Simultaneous participation in another intervention study
- Previous participation in this study
- ... and 2 more (see full listing online)

Locations (17 total)

Ludwig-Maximilians-Universität München, Klinikum Großhadern, München, Bavaria, Germany
Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie, Jena, Germany, Germany
... and 14 more locations